Reanalysis of antidepressant trial finds popular drug ineffective and unsafe for adolescents
BMJ Press Release: 16 September 2015
Results contradict original findings and have important implications for research and practice
Restoring Study 329
BMJ Paper: Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence
- Appendix 1: RIAT audit protocol
- Appendix 2: Supplementary tables A-M
- Appendix 3: Supplementary information on suicidal and self-injurious behaviours in Study 329
- Study 329: Patient problem, intervention, comparison, and outcome (PICO)
Liberating the data from clinical trials
BMJ Editorial: David Henry, Professor, Tiffany Fitzpatrick, Meta-Data Specialist
Liberated trial data have enduring potential to benefit patients, prevent harm, and correct misleading research
No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility
BMJ Feature: Peter Doshi, Associate Editor, The BMJ
As a new data analysis adds weight to calls for retraction of a paper on paroxetine in adolescents, Peter Doshi examines the resistance to action of a professional society, its journal, and an Ivy League university
Editor’s Choice
BMJ editorial by Fiona Godlee, editor in chief, The BMJ 17 September 2015
BMJ Video of Jon Jureidini on Restoring Study 329
Features Dr. Jon Jureidini, Clinical Professor, Critical and Ethical Mental Health Research Group, University of Adelaide, Adelaide, Australia who provides an overview of Restoring Study 329 and its differences with the conclusions of the original Study 329.
BMJ Press Briefing Audio
14 September 2015
